| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $1.06B | Trading Days | 51 |
| 52W High | 23.00 |
| 52W Low | 14.85 |
| % Off High | −14.17% |
| Ann. Volatility (1Y) | 82.15% | Ann. Volatility (3Y) | 82.15% |
| Sharpe (1Y) | 0.37 | Sharpe (3Y) | 0.37 |
| Max Drawdown (1Y) | −23.14% | Max Drawdown (3Y) | −23.14% |
| YTD | −0.50% | Since inception | −0.50% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| FBRX | Forte Biosciences, Inc. | $1.06B | — |
| PCRX | Pacira BioSciences, Inc. | $1.04B | 165.0 |
| SVRA | Savara Inc | $1.08B | — |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.03B | — |
| OPK | OPKO HEALTH, INC. | $1.02B | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.10B | — |
| SDGR | Schrodinger, Inc. | $1.11B | — |
| LBRX | LB PHARMACEUTICALS INC | $1.00B | — |
| AVTX | Avalo Therapeutics, Inc. | $999.3M | — |
| WVE | Wave Life Sciences Ltd. | $1.12B | — |
| BIOA | BioAge Labs, Inc. | $986.4M |
| OLMA | Olema Pharmaceuticals, Inc. | $977.4M | — |
